- Reunion Neuroscience (REUN) (formerly Field Trip Health Ltd.) has appointed Greg Mayes as President and Chief Executive Officer
- Mayes’ initial focus as Reunion’s new President and CEO will be on the successful completion of the company’s Phase 1 clinical trial with its lead asset, RE-104, as well as the planned launch of its Phase 2 study in postpartum depression
- He served as the Engage Therapeutics President and CEO from 2017 until 2020
- Reunion Neuroscience Inc. is a leader in novel psychedelic drug development
- Reunion Neuroscience Inc. opened trading at $2.22 per share
Reunion Neuroscience (REUN) (formerly Field Trip Health Ltd.) has appointed Greg Mayes as President and Chief Executive Officer.
Mayes’ initial focus as Reunion’s new President and CEO will be on the successful completion of the company’s Phase 1 clinical trial with its lead asset, RE-104, as well as the planned launch of its Phase 2 study in postpartum depression, which is expected to commence in 2023.
Mayes will also drive and accelerate Reunion’s pre-clinical RE-200 research, which is focused on the discovery of selective and specific serotonergic psychedelics.
As President and CEO of Antios Therapeutics, a clinical-stage biopharmaceutical company, Mayes led a $100+ million Series B financing with top healthcare investors in 2021.
He served as the Engage Therapeutics President and CEO from 2017 until 2020, when the company was acquired by UCB Pharma for $270 million, following a positive, randomized Phase 2b clinical trial evaluating its lead product candidate, a REST (Rapid Epileptic Seizure Termination) treatment.
“Reunion is on the cusp of clinical breakthroughs, and the company needs leadership with experience in raising the capital we will need to get through the coming FDA trial process,” noted Joseph del Moral, Reunion’s Chairman.
“With decades of experience in drug development, Greg brings an extensive wealth of knowledge and expertise at a pivotal time for Reunion,” he added.
“My goal as President and CEO of Reunion is to lead a company that will boldly disrupt the mental health sector with differentiated serotonergic psychedelic therapies,” stated Mayes.
The company intends to appoint Mayes to its Board of Directors to replace Ronan Levy, Reunion co-founder and current Chairman and CEO of Field Trip Health & Wellness Ltd., who will step down from Reunion’s Board in October 2022.
Reunion Neuroscience Inc. (formerly Field Trip Health Ltd.) is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds.
Reunion Neuroscience Inc. opened trading at $2.22 per share.
